Literature DB >> 23151447

Plasmid IL-12 electroporation in melanoma.

Edward Cha1, Adil Daud.   

Abstract

Intratumoral gene electroporation uses electric charges to facilitate entry of plasmid DNA into cells in a reproducible and highly efficient manner, especially to accessible sites such as cutaneous and subcutaneous melanomas. Effective for locally treated disease, electroporation of plasmid DNA encoding interleukin-12 can also induce responses in untreated distant disease, suggesting that adaptive immune responses are being elicited that can target melanoma-associated antigens. In vivo electroporation with immunomodulatory cytokine DNA is a promising approach that can trigger systemic anti-tumor immune responses without the systemic toxicity associated with intravenous cytokine delivery and potentially offer complete long-term tumor regression.

Entities:  

Keywords:  electrogene transfer; electroporation; gene transfer; interleukin-12; intratumoral immunotherapy; melanoma

Mesh:

Substances:

Year:  2012        PMID: 23151447      PMCID: PMC3601150          DOI: 10.4161/hv.22573

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  40 in total

1.  Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma.

Authors:  L F Glass; M Jaroszeski; R Gilbert; D S Reintgen; R Heller
Journal:  J Am Acad Dermatol       Date:  1997-10       Impact factor: 11.527

Review 2.  Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.

Authors:  Angela M Bodles-Brakhop; Richard Heller; Ruxandra Draghia-Akli
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

3.  Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle.

Authors:  L M Mir; M F Bureau; R Rangara; B Schwartz; D Scherman
Journal:  C R Acad Sci III       Date:  1998-11

4.  Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation.

Authors:  G Rizzuto; M Cappelletti; D Maione; R Savino; D Lazzaro; P Costa; I Mathiesen; R Cortese; G Ciliberto; R Laufer; N La Monica; E Fattori
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.

Authors:  Pierre L Triozzi; Karen O Allen; Ronda R Carlisle; Mark Craig; Albert F LoBuglio; Robert M Conry
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

6.  IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.

Authors:  M Lee Lucas; Loree Heller; Domenico Coppola; Richard Heller
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

7.  Optimization of electroporation parameters for the intramuscular delivery of plasmids in pigs.

Authors:  Amir S Khan; Louis C Smith; Ronald V Abruzzese; Kathleen K Cummings; Melissa A Pope; Patricia A Brown; Ruxandra Draghia-Akli
Journal:  DNA Cell Biol       Date:  2003-12       Impact factor: 3.311

8.  Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.

Authors:  Chi-Feng Lee; Suh-Yran Chang; Dar-Shih Hsieh; Dah-Shyong Yu
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

Review 9.  Electroporation advances in large animals.

Authors:  Scott D Reed; Shulin Li
Journal:  Curr Gene Ther       Date:  2009-08       Impact factor: 4.391

10.  Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Authors:  Adil I Daud; Ronald C DeConti; Stephanie Andrews; Patricia Urbas; Adam I Riker; Vernon K Sondak; Pamela N Munster; Daniel M Sullivan; Kenneth E Ugen; Jane L Messina; Richard Heller
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

View more
  17 in total

Review 1.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

2.  Improved Specificity of Gene Electrotransfer to Skin Using pDNA Under the Control of Collagen Tissue-Specific Promoter.

Authors:  Spela Kos; Natasa Tesic; Urska Kamensek; Tanja Blagus; Maja Cemazar; Simona Kranjc; Jaka Lavrencak; Gregor Sersa
Journal:  J Membr Biol       Date:  2015-04-04       Impact factor: 1.843

Review 3.  Advances in the development of intralesional therapies for melanoma.

Authors:  Daniel Y Wang; Douglas B Johnson
Journal:  Melanoma Manag       Date:  2016-11-29

4.  Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.

Authors:  Samantha K Greaney; Alain P Algazi; Katy K Tsai; Kathryn T Takamura; Lawrence Chen; Christopher G Twitty; Li Zhang; Alan Paciorek; Robert H Pierce; Mai H Le; Adil I Daud; Lawrence Fong
Journal:  Cancer Immunol Res       Date:  2019-12-18       Impact factor: 11.151

5.  Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions.

Authors:  Jeffry Cutrera; Glenn King; Pamela Jones; Kristin Kicenuik; Elias Gumpel; Xueqing Xia; Shulin Li
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 6.  Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.

Authors:  Wojciech Szlasa; Natalia Janicka; Natalia Sauer; Olga Michel; Bernadetta Nowak; Jolanta Saczko; Julita Kulbacka
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

Review 7.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

Review 8.  Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.

Authors:  Natalie Vandeven; Paul Nghiem
Journal:  Immunotherapy       Date:  2016-07       Impact factor: 4.196

9.  Electrotransfer of Plasmid DNA Encoding an Anti-Mouse Endoglin (CD105) shRNA to B16 Melanoma Tumors with Low and High Metastatic Potential Results in Pronounced Anti-Tumor Effects.

Authors:  Tanja Dolinsek; Gregor Sersa; Lara Prosen; Masa Bosnjak; Monika Stimac; Urska Razborsek; Maja Cemazar
Journal:  Cancers (Basel)       Date:  2015-12-24       Impact factor: 6.639

10.  Intricacies for posttranslational tumor-targeted cytokine gene therapy.

Authors:  Jeffry Cutrera; Denada Dibra; Arun Satelli; Xuexing Xia; Shulin Li
Journal:  Mediators Inflamm       Date:  2013-11-27       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.